Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Quote from the Baxter Webcast QA

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Aug 08, 2024 11:32pm

147 Views

Post# 36170753

RE:RE:RE:RE:Quote from the Baxter Webcast QA

My suspicion is that "anyone with access to data" can ascertain with statistical certainty that the Tigris Trial will " confirm" what it sought to prove, even at 125 patients.

The math guys at PE need only make a few assumptions:

- final MB which will impact the assumed final price per filter

-target market size

-ultimate market penetration for PMX in treating ESS

They already know the EBITDA multipliers for FDA approved, exclusive market access, medical devices ( hint: it's more than 15)

MM

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market